menu
    • menu
    [{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Series A Financing","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Portland Investment Counsel Inc.","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Portland Investment Counsel Inc."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Fusion Pharma"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RadioMedix \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"RadioMedix \/ Plus Therapeutics"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Alphamedix","moa":"Somatostatin receptor (SSTR)","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Alphamedix","moa":"Somatostatin receptor (SSTR)","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"64-Cu DOTATATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RadioMedix \/ Undisclosed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Ebrahim Delpassand","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2014","type":"Inapplicable","leadProduct":"68-Ga PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Ebrahim Delpassand","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Ebrahim Delpassand"}]

    Find Clinical Drug Pipeline Developments & Deals by RadioMedix

    Menu

    RadioMedix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RadioMedix and Orano Med Receive Breakthrough Designation for AlphaMedixTM

                            Details : AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy for unresectable, metastatic gastroenteropancreatic neuroendocrine tumors, naïve to peptide receptor therapy.

                            Product Name : Alphamedix

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 12, 2024

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in ...

                            Details : AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitt...

                            Product Name : Alphamedix

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 16, 2023

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac PSMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Me...

                            Details : Through the acquisition of Phase 2 program evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers, strengthens the pipeline of innovative targeted alpha therapies.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : 225-Ac PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Fusion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Portland Investment Counsel Inc.

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Plat...

                            Details : The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix™, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuro...

                            Product Name : Alphamedix

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            October 07, 2022

                            Lead Product(s) : 212-Pb Dotamtate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Portland Investment Counsel Inc.

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

                            Details : Alphamedix is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 10, 2021

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 186-Re Obisbemeda

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug

                            Details : This strategic partnership substantially supports efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            September 02, 2021

                            Lead Product(s) : 186-Re Obisbemeda

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 64-Cu DOTATATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DO...

                            Details : 64-Cu DOTATATE is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 17, 2018

                            Lead Product(s) : 64-Cu DOTATATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET

                            Details : Alphamedix is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 15, 2018

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga PSMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Ebrahim Delpassand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

                            Details : 68-Ga PSMA is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            November 04, 2014

                            Lead Product(s) : 68-Ga PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Ebrahim Delpassand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth